A new private investor along with lead investor bm|t, were convinced of the progress and promise of SmartDyeLivery GmbH from Jena.
Erfurt/Munich/Jena. SmartDyeLivery GmbH has successfully closed a financing round with a business angel investor and current lead investor, bm|t. The young Biotech company from Jena will further develop its innovative nanotechnology for life sciences applications. “With this capital, we are well positioned to take our unique nanotherapy through the next stage of development,” said a pleased Dr. Marc Lehmann, Managing Director of SmartDyeLivery GmbH.
SmartDyeLivery develops functionalized nanoparticles in which therapeutic compounds are enveloped and safely transported to specific organs, which the medicines are targeting. This patented platform delivery technology can be used for a wide range of therapeutic applications and also allows for a unique theranostic use case. Currently the SmartDyeLivery team is focusing on a therapy for sepsis induced liver failure with the goal of reducing the mortality rate of such cases by 90%.
About bm‑t: Erfurt-based, beteiligungsmanagement Thüringen (bm|t) – a subsidiary of the Thuringia Development Bank, is the first address for investments in Thuringia, Germany. bm‑t currently manages eight investment funds with a total volume of 320M EUR. bm‑t invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.
About SmartDyeLivery GmbH: SmartDyeLivery GmbH develops nanoparticle transport for therapeutic, diagnostic, and theranostic applications. The company´s goal is to save patients´ lives by creating new therapy options for medical conditions that were previously either untreatable or extremely difficult to treat.
You can find more information about SmartDyeLivery at www.smartdyelivery.de
Dr. Marc Lehmann